Where it is registered
Each register and historical list with its number of registrations and a few of them.
United States
FDA · 9 registrations
Show all 9New Zealand
PHARMAC (NZ funding schedule) · 1 registration
Taiwan
TFDA · 1 registration
Saudi Arabia
SFDA · 1 registration · Historical list
At a glance
- Registers
- 3
- Historical lists
- 1
- Registrations
- 12
- With their own page
- 10
- Companies
- 2
All medicines with Hydrogen
Human medicines from every register that match Hydrogen by substance or by name, a page at a time, so the count can differ from the registrations above. Strengths and packs are on each medicine’s page.
232 search results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Hydrogenated Ergot Alkaloids | United States | 0.5MG, 1MG | tablet | Not marketed | Ivax Pharms |
| Clopidogrel Teva (hydrogen sulphate) | European Union | Authorised | Teva Pharma B.V. | ||
| AnyCombination | New Zealand | Inj 37.46 mg with sodium dihydrogen phosphate 47.7 mg in 1.5 ml ampoule | Funded | ||
| Eskata | United States | 40% | solution | Not marketed | Aclaris |
| Uralyt-U Granules | Saudi Arabia | Authorised | Rottapharm|Madaus Group | ||
| Oximen 3% Solución Cutánea y Concentrado Para Solución Bucal | Spain | 3 g | solución cutánea | Marketed | Laboratorio Reig Jofre, S.A. |
| AGUA OXIGENADA FORET 3 % solución cutánea y concentrado para solución bucal | Spain | 7575 mg | solución cutánea | Marketed | Peroxfarma S.A. |
| Agua Oxigenada Cuve 30 MG/ML Solucion Cutanea y Concentrado Para Solucion Bucal | Spain | 3 g | solución cutánea | Marketed | Pharmex Advanced Laboratories S.L. |
| SibnayalCombination | European Union | Authorised | Advicenne S.A. | ||
| Acolora Polvo Para Solucion Oral en SobreCombination | Spain | 13125 mg + 350,7 mg + 178.5 mg + 46,6 mg | polvo para solucion oral en sobre | Authorised | Lainco S.A. |
| Clinimix N14 G30 E, oplossing voor infusieCombination | Netherlands | Oplossing voor infusie | Authorised | Baxter B.V. | |
| Clinimix N17 G35 E, oplossing voor infusieCombination | Netherlands | Oplossing voor infusie | Authorised | Baxter B.V. | |
| Clinimix N9 G15 E, oplossing voor infusieCombination | Netherlands | Oplossing voor infusie | Authorised | Baxter B.V. | |
| Apo-Rivastigmine | Canada | 3 MG | Capsule | Marketed | Apotex INC |
| Apo-Rivastigmine | Canada | 4.5 MG | Capsule | Marketed | Apotex INC |
| Apo-Rivastigmine | Canada | 6 MG | Capsule | Marketed | Apotex INC |
| Apo-Rivastigmine | Canada | 1.5 MG | Capsule | Marketed | Apotex INC |
| Exelon | Canada | 6 MG | Capsule | Marketed | Knight Therapeutics INC. |
| Exelon | Canada | 3 MG | Capsule | Marketed | Knight Therapeutics INC. |
| Exelon | Canada | 4.5 MG | Capsule | Marketed | Knight Therapeutics INC. |
| Exelon | Canada | 1.5 MG | Capsule | Marketed | Knight Therapeutics INC. |
| Exelon | Canada | 2 MG / ML | Solution | Marketed | Knight Therapeutics INC. |
| Jamp Rivastigmine | Canada | 6 MG | Capsule | Marketed | Jamp Pharma Corporation |
| Jamp Rivastigmine | Canada | 1.5 MG | Capsule | Marketed | Jamp Pharma Corporation |
| Jamp Rivastigmine | Canada | 3 MG | Capsule | Marketed | Jamp Pharma Corporation |